nano-S/MARt CAR T-cell therapy

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Namenano-S/MARt CAR T-cell therapy

Drug Alias Nameanti-CEA CAR T-cell therapy (Heidelberg University/Deutsches Krebsforschungszentrum DKFZ)nS/MARt-CEA-CAR-T cellscarcinoembryonic antigen-specific adoptive cell therapy (Deutsches Krebsforschungszentrum)

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionCarcinoembryonic antigen related cell adhesion molecule 5 modulators

TargetsCarcinoembryonic antigen related cell adhesion molecule 5

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryGermany

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesHeidelberg University

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesGerman Cancer Research Center (Dkfz)Heidelberg University

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A